CN104383183A - 一种治疗非酒精性脂肪肝的药物组合物 - Google Patents
一种治疗非酒精性脂肪肝的药物组合物 Download PDFInfo
- Publication number
- CN104383183A CN104383183A CN201410749915.2A CN201410749915A CN104383183A CN 104383183 A CN104383183 A CN 104383183A CN 201410749915 A CN201410749915 A CN 201410749915A CN 104383183 A CN104383183 A CN 104383183A
- Authority
- CN
- China
- Prior art keywords
- parts
- fatty liver
- alcoholic fatty
- rhizoma
- liver disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 38
- 210000000952 spleen Anatomy 0.000 claims abstract description 30
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 16
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 16
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 12
- 206010036790 Productive cough Diseases 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 208000024794 sputum Diseases 0.000 claims description 6
- 210000003802 sputum Anatomy 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 3
- 239000012567 medical material Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 abstract description 28
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 14
- 208000026435 phlegm Diseases 0.000 abstract description 14
- 208000002193 Pain Diseases 0.000 abstract description 13
- 239000008280 blood Substances 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 235000013305 food Nutrition 0.000 abstract description 7
- 230000014759 maintenance of location Effects 0.000 abstract description 6
- 230000007812 deficiency Effects 0.000 abstract description 4
- 230000004087 circulation Effects 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 235000008216 herbs Nutrition 0.000 abstract 2
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 235000014493 Crataegus Nutrition 0.000 abstract 1
- 241001092040 Crataegus Species 0.000 abstract 1
- 241000146384 Glaux Species 0.000 abstract 1
- 241000212322 Levisticum officinale Species 0.000 abstract 1
- 241001522129 Pinellia Species 0.000 abstract 1
- 239000001645 levisticum officinale Substances 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 description 26
- 231100000240 steatosis hepatitis Toxicity 0.000 description 25
- 208000004930 Fatty Liver Diseases 0.000 description 24
- 206010019708 Hepatic steatosis Diseases 0.000 description 24
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 208000011580 syndromic disease Diseases 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 11
- 235000009508 confectionery Nutrition 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000012886 Vertigo Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 231100000889 vertigo Toxicity 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 238000013139 quantization Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 1
- 208000018779 Globus Sensation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 231100000594 drug induced liver disease Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229940043175 silybin Drugs 0.000 description 1
- 235000014899 silybin Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 235000021476 total parenteral nutrition Nutrition 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于医药技术领域,具体涉及一种治疗非酒精性脂肪肝的药物组合物。所述药物组合物包括如下组份:白术、茯苓、泽泻、柴胡、半夏、远志、山茱萸、山楂、三七、肉桂、川芎。本药物组合物均为中草药,全方配伍合理,具有健脾消积、疏肝止痛、行气活血的作用,对于非酒精性脂肪肝尤其是脾虚痰湿型非酒精性脂肪肝疗效确切,适合临床推广应用。
Description
技术领域
本发明属于医药技术领域,具体涉及一种治疗非酒精性脂肪肝的药物组合物。
背景技术
脂肪肝是指肝细胞内甘油三酯(TG)蓄积过多的病理改变,当肝细胞内脂质蓄积超过肝湿重的5-10%或组织学上每单位面积见1/3以上肝细胞脂变时,称为脂肪肝。根据病因分类,分为酒精性脂肪肝和非酒精性脂肪肝,除外酒精和其他明确的损肝因素所致的脂肪肝称为非酒精性脂肪肝(non alcoholics fat fiver disease,NAFLD),非酒精性脂肪肝NAFLD包括单纯性脂肪肝和非酒精性脂肪性肝炎(nonalcoholic stcatohepatitis,NASH)以及脂肪性肝硬化等三种类型。
脂肪肝系近代西医学的病名,中医古代典籍并无脂肪肝之病名。现代中医书籍中的脂肪肝病名实系根据西医学而来的。其病位在肝,与脾胃肾关系密切,大多将其归属于“胁痛”、“积聚”、“痰饮”、“鼓胀”等范畴。多数医家认为,脂肪肝多为饮食不节,过食肥甘厚味,或恣饮酒浆,或情志不调,或湿热疫毒,或久病体虚等致肝失疏泄、脾失健运,湿热内蕴,痰浊郁结,瘀血阻滞,湿痰瘀阻互结,痹阻肝脏脉络而形成脂肪肝。中医辨病与辩证相结合的原则贯穿于脂肪肝治疗的始终,辨证论治是中医的精髓,运用中医整体观念,将基本矛盾与疾病当前阶段的主要矛盾相结合,根据病机演变规律,深入研究疾病发展的本质,随证化裁,综合论治,体现了中医治疗的前瞻性与灵活性。
发明内容
本发明提供了一种治疗非酒精性脂肪肝的新的药物组合物,该药物组合物起效快,疗效好,毒副作用小,它由以下原料制得:白术、茯苓、泽泻、柴胡、半夏、远志、山茱萸、山楂、三七、肉桂、川芎。
本发明所述药物组合物中,所述白术,苦、甘,温。归脾、胃经。健脾益气,燥湿利水,止汗,安胎。用于脾虚食少,腹胀泄泻,痰饮眩悸,水肿,自汗,胎动不安。土白术健脾,和胃,安胎。用于脾虚食少,泄泻便溏,胎动不安。
茯苓,甘、淡、平。归心、脾、肺、肾经。渗湿利水,健脾和胃,宁心安神。用于小便不利,水肿胀满,痰饮咳逆,呕吐,脾虚食少,泄泻,心悸不安,失眠健忘,遗精白浊等。
泽泻,甘,寒。归肾、膀胱经。利小便,清湿热。用于小便不利,水肿胀满,泄泻尿少,痰饮眩晕,热淋涩痛;高血脂。
柴胡,苦,微寒。归肝、胆经。和解表里,疏肝,升阳。用于感冒发热,寒热往来,胸胁胀痛,月经不调,子官脱垂,脱肛。
半夏,辛,温;有毒。归脾、胃、肺经。燥湿化痰,降逆止呕,消痞散结。用于痰多咳喘,痰饮眩悸,风痰眩晕,痰厥头痛,呕吐反胃,胸脘痞闷,梅核气。
远志,苦、辛、温。归心、肾、肺经。安神益智,祛痰,消肿。用于心肾不交引起的失眠多梦,健忘惊悸,神志恍惚,咳痰不爽,疮疡肿毒,乳房肿痛。
山茱萸,酸、涩,微温。归肝、肾经。补益肝肾,涩精固脱。用于眩晕耳鸣,腰膝酸痛,阳痿遗精,遗尿尿频,崩漏带下,大汗虚脱。内热消渴。
山楂,酸、甘、微温。归脾、胃、肝经。消食健胃,行气散瘀。用于肉食积滞,胃脘胀满,泻痢腹痛,瘀血经闭,产后瘀阻,心腹刺痛,疝气疼痛;高脂血症。焦山楂消食导滞作用增强。用于肉食积滞,泻痢不爽。
三七,味甘,微苦,性湿。归肝,胃,心,肺,大肠经。止血;散血;定痛。主跌扑瘀肿,胸痹绞痛,症瘕;血瘀经闭;痛经;产后瘀阴腹痛;疮痈肿痛。
肉桂, 辛、甘,热。归脾、肾、心、肝经。补火助阳,散寒止痛,温经通脉。
川芎,味辛;性温归肝、胆、心包经。活血祛瘀;行气开郁;祛风止痛。主月经不调;经闭痛经;产后瘀滞腥痛;症瘕肿块;胸胁疼痛;头痛眩晕;风寒湿痹;跌打损伤;痈疽疮疡
本发明药物组合物选用白术、茯苓健脾益气、渗湿利水,为君药,泽泻、柴胡疏肝利胆、活血止痛,为臣药,半夏、远志、山茱萸燥湿祛痰、补益肝肾为佐药;山楂、三七、肉桂、川芎行气活血、散瘀止痛为使药,全方配伍使用,共奏健脾消积、疏肝止痛、行气活血之功,达到治疗非酒精性脂肪肝的目的。
为解决其技术问题所采用的技术方案是:所述治疗非酒精性脂肪肝的药物组合物,由下列重量份配比的药物原料组成:白术15-25份,茯苓15-25份,泽泻10-20份,柴胡10-20份,半夏5-10份,远志5-10份,山茱萸5-10份,山楂1-5份,三七1-5份,肉桂1-5份,川芎1-5份。
本发明的优选技术方案是,所述本发明药物组合物由以下重量份的原料制得:白术20份,茯苓20份,泽泻15份,柴胡15份,半夏8份,远志8份,山茱萸7份,山楂3份,三七3份,肉桂3份,川芎3份。
本发明还提供了所述药物组合物的制备方法,具体包括如下步骤:将上述重量份的原料白术、茯苓、泽泻、柴胡、半夏、远志、山茱萸、山楂、三七、肉桂、川芎混合后粉碎,加药材总质量3倍量的水煎煮2次,每次30min,过滤除渣取汁合并,并将滤液浓缩至60℃时,其相对密度为1.31-1.35的稠膏,即得。
本领域技术人员可以在制得的本发明药物活性成分基础上直接入药服用或加入药剂学上可接受的辅料按常规工艺制备成所需口服制剂。如可以制成常用的片剂(分散片、泡腾片、口腔崩解片、含片、咀嚼片、泡腾片)、胶囊剂 (硬胶囊、软胶囊剂)、颗粒剂、丸剂(滴丸剂)、散剂等固体制剂形式的口服药物,也可以制成糖浆、口服液、水剂、合剂、汤剂等液体制剂形式的口服药物。因此,该药物组合物中除有效成分外,还可以含有药学上可以接受的辅料。优选的是,本发明药物组合物按照常规制备工艺制备成口服液、水剂、冲剂、胶囊剂或散剂等。
本发明还请求保护上述药物组合物在制备治疗脂肪肝特别是在制备治疗脾虚痰湿型脂肪肝药物中的用途。通过临床试验可知,两组患者治疗3个疗程后疗效评定结果,治疗组治愈率为36.7%,对照组为13.3%,治愈率比较,P值均<0.05,有显著性差异;总有效率治疗组为93.3%,对照组为56.7%,总有效率比较,P值均<0.05,有显著性差异。在安全性评价中,本发明治疗组有1人出现轻微胃肠道恶心;对照组中有3人出现轻微的胃肠道恶心,有1人出现轻度胸闷,均无需特殊处理,数日后均缓解可继续服药;两组患者服药前后的血常规、尿常规、肾功能、心电图等检查未发现明显异常。由此说明使用本发明所述药物组合物治疗脂肪肝特别是治疗属于脾虚痰湿型脂肪肝疗效确切,起到了标本兼治的显著效果,安全可靠,可作为治疗脾虚痰湿型脂肪肝的有效方法,在临床中值得推广使用。
本发明药物组合物为天然纯中药制剂,原药易得、成本低廉,遵循中医的处方用药原则,不良反应和副作用显著降低,安全系数高,经临床应用验证,其疗效确切,药性平和,未出现毒副作用及严重不良反应,临床观察总有效率达到90%以上,同时本发明制备的药品用药方便,提高了脂肪肝患者的用药依从性,提高了患者的生活质量。
具体实施方式
以下通过具体实施例进一步描述本发明,但是本发明不仅仅限于以下具体实施例。在本发明的范围内或者在不脱离本发明的内容、精神和范围内,对本发明进行的变更、组合或替换,对于本领域的技术人员来说是显而易见的,且包含在本发明的范围之内。
实施例1
按以下重量份称取本发明各原料:白术20份,茯苓20份,泽泻15份,柴胡15份,半夏8份,远志8份,山茱萸7份,山楂3份,三七3份,肉桂3份,川芎3份。
制备工艺如下:将上述重量份的原料白术、茯苓、泽泻、柴胡、半夏、远志、山茱萸、山楂、三七、肉桂、川芎混合后粉碎,加药材总质量3倍量的水煎煮2次,每次30min,过滤除渣取汁合并,并将滤液浓缩至60℃时,其相对密度为1.31-1.35的稠膏,即得。本领域技术人员可以在此基础上直接入药服用或加入辅料用常规制剂工艺制得口服液、水剂、冲剂、胶囊剂或散剂等常用的口服制剂。
使用本发明药物组合物治疗非酒精性脂肪肝证时,服用所制备的口服液,每次5mL药液,一日2次,每毫升口服液含生药量0.5g。服用所制备的冲剂,每次5g,一日2次,每克冲剂含生药量0.5g。
实施例2
按以下重量份称取本发明各原料:白术15份,茯苓15份,泽泻10份,柴胡10份,半夏5份,远志5份,山茱萸5份,山楂1份,三七1份,肉桂1份,川芎1份。
实施例3
按以下重量份称取本发明各原料:白术25份,茯苓25份,泽泻20份,柴胡20份,半夏10份,远志10份,山茱萸10份,山楂5份,三七5份,肉桂5份,川芎5份。
实施例4
按以下重量份称取本发明各原料:白术15份,茯苓25份,泽泻10份,柴胡20份,半夏5份,远志10份,山茱萸5份,山楂5份,三七1份,肉桂5份,川芎1份。
实施例5
按以下重量份称取本发明各原料:白术25份,茯苓15份,泽泻20份,柴胡10份,半夏10份,远志5份,山茱萸10份,山楂1份,三七5份,肉桂1份,川芎5份。
实施例2-5的制备工艺同实施例1。
实施例6本发明药物组合物治疗非酒精性脂肪肝的临床观察
1病例资料:选择医院门诊就诊的符合非酒精性脂肪肝(脾虚痰湿证)诊断标准的患者60例。采用随机分组、平行对照的方法进行研究。
所纳入观察对象中,治疗组:30例,其中男20例,女10例,年龄23-62岁,平均年龄46.8岁,病程1月-8年,平均病程4.6年,轻度13例、中度14例、重度3例。对照组:30例,其中男21例,女9例,年龄24-61岁,平均年龄47.2岁,病程1月-9年,平均病程4.5年,轻度14例、中度13例、重度3例。两组患者年龄、性别、病情分布及其它一般资料比较无显著性差异,具有可比性。
2诊断依据:
1)西医诊断标准:
参照执行中华医学会肝脏病学分会脂肪肝和酒精性肝病学组 2006 年 2 月修订的《非酒精性脂肪性肝病诊疗指南》。
(1)临床诊断标准
凡具备下列第①-⑤项和第⑥或第⑦项中任何一项者即可诊断为 NAFLD。
①无饮酒史或饮酒折含乙醇量男性每周小于140g,女性每周小于70g;
②除外病毒性肝炎、药物性肝病、全胃肠外营养、肝豆状核变性等可导致脂肪肝的特定疾病;
③除原发疾病临床表现外,可有乏力、消化不良、肝区隐痛、肝脾肿大等非特异性症状及体征;
④可有体重超重和(或)内脏性肥胖、空腹血糖增高、血脂紊乱、高血压等代谢综合征相关组分;
⑤血清转氨酶和γ-谷氨酰转肽酶水平可有轻至中度增高(小于5倍正常值上限),通常以丙氨酸氨基转移酶(ALT)增高为主;
⑥肝脏影像学表现符合弥漫性脂肪肝的影像学诊断标准;
⑦肝活体组织检查组织学改变符合脂肪性肝病的病理学诊断标准。
(2)影像学诊断标准
B超诊断标准:
①肝区近场回声弥漫性增强(强于肾脏和脾脏),远场回声逐渐衰减;
②肝内管道结构显示不清;
③肝脏轻至中度肿大,边缘角圆钝;
④彩色多普勒血流显象提示肝内彩色血流信号减少或不易显示,但肝内血管走向正常;
⑤肝右叶包膜及横膈回声显示不清或不完整。
具备上述第①项及第②-④项中一项者为轻度脂肪肝;具备上述第①项及第②-④项中两项者为中度脂肪肝;具备上述第①项以及②-④项中两项和第⑤项者为重度脂肪肝。
CT 诊断标准:
弥漫性肝脏密度降低,肝脏与脾脏的CT值之比小于或等于 1。弥漫性肝脏密度降低,肝/脾CT比值≤1.0 但大于0.7者为轻度;肝/脾CT比值≤0.7但大于0.5者为中度;肝/脾CT比值≤0.5者为重度。
2)中医证候诊断标准:
参照《中药新药临床研究指导原则》,结合脂肪肝临床特点和相关文献报道,拟定以下标准。
(1)脾虚痰湿证:胁肋不适,体倦乏力,形体肥胖;恶心纳差,大便不适;舌质淡红或红,苔白或黄,薄、厚或腻,或有齿痕;脉弦细、滑或濡缓。
(2)主要证候分级量化标准
表1. 主要证候分级量化标准
3纳入标准:
(1)年龄18-65岁之间;
(2)符合脾虚痰湿证中医证候诊断及西医诊断标准者;
(3)3个月内未使用对肝肾功能有严重影响的药物,1个月内未参加过其它药物试验者;
(4)签署“知情同意书”者;
4排除标准:
(1)未签署“知情同意书”者。
(2)其他如酒精、皮质激素、药物或毒物损伤、营养不良、慢性心衰及妊娠等所致脂肪肝。
(3)合并病毒性肝炎、肝硬化、肝实体肿瘤,以及局灶性脂肪肝不能排除再生结节、血管瘤或转移瘤者。
(4)合并心、肺、肾等重要脏器严重器质性疾病或造血系统严重原发性疾病,糖尿病出现严重并发症者,及其它需要紧急处理的疾病;各种程度的精神病者;严重创伤或重大手术者。
(5)妊娠或准备妊娠的妇女,哺乳期妇女。
(6)已知或可能对试验药物及其组分过敏者。
5剔除和脱落标准:
(1)病例入选后,发现不符合纳入标准或符合排除标准者;
(2)出现严重不良事件,根据医生判断应停止该病例临床试验者;
(3)病例入选后资料不全或未按规定用药者;
(4)试验过程中,受试者依从性差,影响疗效评价者。
6用法用量:
治疗组:取实施例1制备的冲剂,每次服用5g,一日2次,每克冲剂含生药量0.5g。
对照组:水飞蓟宾胶囊(国药准字H20040299),口服,一日3次,一次3粒。
两组均是4周为一疗程,服用3个疗程后观察结果。
基础治疗:两组患者在正常按时服药的基础上,嘱之饮食控制:低脂低糖高维生素饮食,多食新鲜蔬菜水果,适食面类制品,少食高胆固醇食物(如动物内脏、蛋黄等),慎食辛温刺激类食物(如辣椒、牛羊肉等)、高糖食物,忌食高脂食物及含酒精的饮料。
7中医证候疗效评定标准
临床痊愈:临床症状消失或基本消失,证候积分下降≥95%;
显效:症状、体征明显改善,证候积分减少≥70%;
有效:症状、体征明显改善,证候积分减少≥30%;
无效:症状、体征均无明显改善,甚或加重,证候积分减少不足30%。
注:计算公式(尼莫地平法)为:(治疗前积分-治疗后积分)/治疗前积分×100%。
8治疗效果:
治疗过程中无剔除和脱落病例,均完成临床观察。
两组患者治疗3个疗程后疗效评定结果,治疗组治愈率为36.7%,对照组为13.3%,治愈率比较,P值均<0.05,有显著性差异;总有效率治疗组为93.3%,对照组为56.7%,总有效率比较,P值均<0.05,有显著性差异。另外,两组在肝功能、B超及CT方面比较,治疗组也显著优于对照组(P<0.05),有显著性差异。
表2.治疗组和对照组的疗效比较
在安全性评价中,治疗组有1人出现轻微胃肠道恶心;对照组中有3人出现轻微的胃肠道恶心,有1人出现轻度胸闷,无需特殊处理,数日后均缓解可继续服药;两组患者服药前后的血常规、尿常规、肾功能、心电图等检查未发现明显异常。
以上说明使用本发明所述药物组合物治疗非酒精性脂肪肝特别是治疗属于脾虚痰湿型非酒精性脂肪肝疗效确切,安全可靠,可作为治疗脾虚痰湿型非酒精性脂肪肝的有效方法,在临床中值得推广使用。
Claims (8)
1.一种治疗非酒精性脂肪肝的药物组合物,其特征在于由以下重量份的原料制得:白术15-25份,茯苓15-25份,泽泻10-20份,柴胡10-20份,半夏5-10份,远志5-10份,山茱萸5-10份,山楂1-5份,三七1-5份,肉桂1-5份,川芎1-5份。
2.如权利要求1所述的治疗非酒精性脂肪肝的药物组合物,其特征在于由以下重量份的原料制得:白术20份,茯苓20份,泽泻15份,柴胡15份,半夏8份,远志8份,山茱萸7份,山楂3份,三七3份,肉桂3份,川芎3份。
3.如权利要求1或2所述的治疗非酒精性脂肪肝的药物组合物,其特征在于:所述药物组合物是口服制剂。
4.如权利要求3所述的治疗非酒精性脂肪肝的药物组合物,其特征在于:所述口服制剂为口服液、水剂、冲剂、胶囊剂或散剂。
5.如权利要求4所述的治疗非酒精性脂肪肝的药物组合物,其特征在于:所述口服制剂为冲剂。
6.一种制备如权利要求3所述的治疗非酒精性脂肪肝的药物组合物的方法,其特征在于包括如下步骤:将重量份的原料白术、茯苓、泽泻、柴胡、半夏、远志、山茱萸、山楂、三七、肉桂、川芎混合后粉碎,加药材总质量3倍量的水煎煮2次,每次30min,过滤除渣取汁合并,并将滤液浓缩至60℃时,其相对密度为1.31-1.35的稠膏,在制得的本发明药物活性成分基础上直接入药服用或加入药剂学上可接受的辅料按常规工艺制备成所需口服制剂。
7.权利要求1或2所述的药物组合物在制备治疗非酒精性脂肪肝药物中的用途。
8.如权利要求7所述的用途,其特征在于:所述非酒精性脂肪肝为脾虚痰湿型非酒精性脂肪肝。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410749915.2A CN104383183A (zh) | 2014-12-10 | 2014-12-10 | 一种治疗非酒精性脂肪肝的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410749915.2A CN104383183A (zh) | 2014-12-10 | 2014-12-10 | 一种治疗非酒精性脂肪肝的药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104383183A true CN104383183A (zh) | 2015-03-04 |
Family
ID=52601207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410749915.2A Withdrawn CN104383183A (zh) | 2014-12-10 | 2014-12-10 | 一种治疗非酒精性脂肪肝的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104383183A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107029074A (zh) * | 2017-06-07 | 2017-08-11 | 成都中医药大学附属医院 | 一种治疗脂肪肝的药物组合物及制备方法与用途 |
CN109718316A (zh) * | 2019-02-25 | 2019-05-07 | 杨倩 | 一种治疗非酒精性脂肪性肝病的中药组合物及其制备方法 |
CN116549563A (zh) * | 2023-07-05 | 2023-08-08 | 北京盛际中医药研究院 | 一种疏肝利胆的中药组合物及其制备方法和应用 |
CN118320043A (zh) * | 2024-06-13 | 2024-07-12 | 长春中医药大学 | 一种治疗非酒精性脂肪性肝炎的健脾通络降浊组合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103432528A (zh) * | 2013-08-23 | 2013-12-11 | 冯庄明 | 一种治疗非酒精性脂肪肝的中药制剂 |
-
2014
- 2014-12-10 CN CN201410749915.2A patent/CN104383183A/zh not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103432528A (zh) * | 2013-08-23 | 2013-12-11 | 冯庄明 | 一种治疗非酒精性脂肪肝的中药制剂 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107029074A (zh) * | 2017-06-07 | 2017-08-11 | 成都中医药大学附属医院 | 一种治疗脂肪肝的药物组合物及制备方法与用途 |
CN109718316A (zh) * | 2019-02-25 | 2019-05-07 | 杨倩 | 一种治疗非酒精性脂肪性肝病的中药组合物及其制备方法 |
CN116549563A (zh) * | 2023-07-05 | 2023-08-08 | 北京盛际中医药研究院 | 一种疏肝利胆的中药组合物及其制备方法和应用 |
CN116549563B (zh) * | 2023-07-05 | 2023-09-19 | 北京盛际中医药研究院 | 一种疏肝利胆的中药组合物及其制备方法和应用 |
CN118320043A (zh) * | 2024-06-13 | 2024-07-12 | 长春中医药大学 | 一种治疗非酒精性脂肪性肝炎的健脾通络降浊组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104189789A (zh) | 一种治疗急性传染性黄疸型肝炎的中药组合物 | |
CN105727145A (zh) | 用于治疗脾虚痰湿证型高脂血症的中药药物 | |
CN104383183A (zh) | 一种治疗非酒精性脂肪肝的药物组合物 | |
CN103341127B (zh) | 一种配合血液透析治疗尿毒症的中药及制备方法 | |
CN105535575A (zh) | 减轻化疗副反应的药物 | |
CN105497780A (zh) | 和胃护膜止痛汤 | |
CN104721256A (zh) | 一种安胃疡提取物及其制备方法和医药用途 | |
CN104548029A (zh) | 一种治疗胃脘痛的药物组合物 | |
CN104623314A (zh) | 用于治疗口干口苦的药物组合物及其制备方法 | |
CN104474202B (zh) | 一种治疗厌食的药物组合物 | |
CN103585449A (zh) | 用于治疗偏头痛的中药组合物 | |
CN103041233A (zh) | 一种治疗小儿腹泻的药物组合物及其制备方法 | |
CN106177268A (zh) | 一种治疗阳痿的中药组合物及其制备方法 | |
CN105233078A (zh) | 一种用于治疗病毒性肝炎的中药组合物 | |
CN104887950A (zh) | 一种治疗乳痈的中药组合物 | |
CN104352717A (zh) | 一种治疗脾气虚弱型便血的中药制剂及其制备方法 | |
CN103877484A (zh) | 一种治疗慢性肠炎的中药口服液 | |
CN104491316B (zh) | 一种治疗中气不足型前列腺增生症的中药制剂 | |
CN103705856B (zh) | 用于预防放化疗急性放射反应的中药组合物 | |
CN102579713B (zh) | 治疗儿童肥胖症的中药及制备方法 | |
CN105267940A (zh) | 一种预防和治疗胃溃疡的中药组合物及其制备方法 | |
CN106266985A (zh) | 一种可有效治疗乙型肝炎的丸剂药物及其制备方法 | |
CN104587246B (zh) | 一种治疗胃脘痛的中药制剂及其制备方法 | |
CN105194588A (zh) | 一种治疗肝硬化的中药制剂 | |
CN104524149A (zh) | 一种防治急性肾炎的药物组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20150304 |